Search

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.

ABIC-COPD

Discover the ABIC Fund, developed to advance health innovation projects in the area of respiratory diseases, like COPD, for Alberta-based investigators.

Boehringer Ingelheim - Value Through Innovation

INSPIRED

Read more about INSPIRED, aimed at expanding a hospital-to-home program to better support people living with chronic obstructive pulmonary disease (COPD).

ABILD02

The ABILD02 partnership aims to understand ILD patients needing oxygen therapy, identifying facilitators and barriers to its use via stakeholder consultations.

Pommeraie collaborative COPD strategy

La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

ABILD

ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

France

Scleroderma

Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

stargardt-disease-infographic

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Human Health Partnering

Science Stories

Science and Innovation - Human Health Innovation - Science Stories

AHEAD Program

The partnership program led by Boehringer Ingelheim Canada to address gaps in Canada’s health system for people living with T2D and heart failure. Click to read more.

COACH Program

The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

ABIC-COPD

Boehringer Ingelheim - Value Through Innovation

INSPIRED

ABILD02

Pommeraie collaborative COPD strategy

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

ABILD

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Hypertension

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

France

Scleroderma

Diabetes

Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project

stargardt-disease-infographic

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Human Health Partnering

Science Stories

AHEAD Program

COACH Program

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 